Artelo Biosciences Inc ARTL
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Artelo Biosciences to Present ART27.13 Data Demonstrating Potential to Treat Chemotherapy-Induced Neuropathic Pain at the IASP 2026 World Congress on Pain
-
Artelo Biosciences to Showcase First-in-Human FABP5 Inhibitor ART26.12 as a Novel Approach to Pain Treatment at IASP 2026 World Congress on Pain
-
Artelo Biosciences Selected for its First-Ever Company Presentation at BIO-Europe 2026 to Showcase Clinical Progress and Expanding Potential of its Novel FABP5 Inhibitor Platform
-
Artelo Biosciences Files New Provisional Patent Application Covering ART27.13 for Obesity, Alone and in Combination with GLP-1 Receptor Agonists, Following Unexpected Nonclinical Findings
-
Artelo Biosciences Announces ART27.13 Achieved Weight Loss Comparable to Semaglutide as a Monotherapy and Doubled Weight Loss in Combination with Semaglutide in a Nonclinical Model of Obesity
-
Artelo Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference
-
Artelo Biosciences Announces Reverse Stock Split
-
Artelo Biosciences Secures Notice of Allowance in Japan for Patent Claims for the Intended Commercial Formulation of ART27.13
Trading Information
- Previous Close Price
- $2.40
- Day Range
- $2.27–2.27
- 52-Week Range
- $2.13–178.83
- Bid/Ask
- $2.22 / $2.94
- Shares Outstanding
- 547,774.00
- Market Cap
- $1.28M
- Volume/Avg
- 6,794 / 471,419
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 7
- Website
- https://www.artelobio.com
Valuation
|
Metric
|
ARTL
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.22 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
ARTL
|
|---|---|
Quick Ratio | 2.89 |
Current Ratio | 3.00 |
Interest Coverage | −36.93 |
Quick Ratio
ARTL
Profitability
|
Metric
|
ARTL
|
|---|---|
Return on Assets (Normalized) | −160.91% |
Return on Equity (Normalized) | −585.31% |
Return on Invested Capital (Normalized) | −407.53% |
Return on Assets
ARTL
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|%?M$?& | LOCK|q#!D | $135B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|H?Gj$!b | LOCK|&Qcz> | $101B | |||
| Moderna Inc
MRNA
| LOCK|&m!>@^ | LOCK|C? | $91B | |||
| argenx SE ADR
ARGX
| LOCK|pK^mf<G | LOCK|hQ! | $56B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|hPPHYMf | LOCK|T^ | $41B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|GCMmfs$# | LOCK|l&lX | $30B | |||
| Incyte Corp
INCY
| LOCK|V<!#^Vr | LOCK|!b | $24B | |||
| BioNTech SE ADR
BNTX
| LOCK|DDH!Jy! | LOCK|CN | $22B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|h#m!?kg | LOCK|^b<#D | $21B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|D%zv@J | LOCK|rD | $15B |
United States